Press Releases.
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
February 17, 2016- RG-101 Containing Regimen Has Potential to Reduce Harvoni®, Olysio®, or Daklinza™ Rx to 4 Week Duration -
-
January 21, 2016- Additional studies on track for enrollment in H12016 with multiple data read-outs expected throughout 2016 -
-
December 18, 2015-Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015-
-
November 05, 2015-Expanded Development of RG-101 through Clinical Trial Collaboration with GSK to Achieve Potential Single Visit HCV Therapy -
-
November 03, 2015- Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients